Corpus Intelligence IC Memo — RICHMOND STATE HOSPITAL 2026-04-26 13:27 UTC
IC Memo — RICHMOND STATE HOSPITAL
Investment Committee Memorandum | IN | 213 beds | Grade C | EBITDA uplift $249K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

RICHMOND STATE HOSPITAL

CCN 154018 | WAYNE, IN | 213 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

RICHMOND STATE HOSPITAL is a 213-bed under-performing / distressed in WAYNE, IN with $3.2M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 0.0% Medicare, 8.2% Medicaid, and 91.8% commercial.

Thesis: Undervalued. Our ML models identify $249K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -1133.5% (+780bps).

Net Revenue HCRIS$3.2M
Current EBITDA COMPUTED$-36.5M
Operating Margin COMPUTED-100.0%
Occupancy HCRIS71.3%
Revenue / Bed COMPUTED$15K
Net-to-Gross HCRIS2.8%
Distress Probability ML42.2%

2. Market Context & Competitive Position

171
IN Hospitals
-1.1%
State Median Margin
42
Comparable Hospitals

IN has 171 Medicare-certified hospitals with a median operating margin of -1.1%. The target's margin of -100.0% places it below the state median. Among 42 size-comparable peers (106-426 beds), the median margin is 4.6%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (106-426), prioritizing same-state peers. 42 hospitals in the comp set.

HospitalStateBedsRevenueMargin
RICHMOND STATE HOSPITAL (Target)IN213$3.2M-100.0%
COMMUNITY HEALTH NETWORK INC.IN387$1.24B16.4%
FRANCISCAN HEALTH INDIANAPOLISIN401$891.4M-0.3%
ASCENSION ST. VINCENT EVANSVILIN346$671.8M11.4%
COMMUNITY HOSPITALIN405$615.1M6.0%
UNION HOSPITAL INC.IN258$581.9M3.8%
LUTHERAN HOSPITAL OF INDIANAIN335$580.1M3.8%
COMMUNITY HOSPITAL OF INDIANA IN340$565.2M12.0%
ESKENAZI HEALTHIN314$562.3M-50.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $249K (780bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Denial Rate Reduction12.0%6.5%$70K+218bp12mo
Net Collection Rate93.5%97.0%$67K+210bp18mo
Cost to Collect4.5%2.5%$64K+200bp12mo
A/R Days Reduction5200.0%3800.0%$39K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+30bp6mo

5. EBITDA Bridge

Denial Rate Reduction
$70K
Net Collection Rate
$67K
Cost to Collect
$64K
A/R Days Reduction
$39K
Clean Claim Rate
$10K
Total EBITDA Uplift$249K
Current EBITDA$-36.5M
+ RCM Uplift+$249K
Pro Forma EBITDA$-36.2M
Current Margin-100.0%
Pro Forma Margin-1133.5%
WC Released (1x)$123K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-56.1M$-238.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-56.1M$-280.1M0.00x-100.0%
Bull Case9.0x11.0x$-50.5M$-297.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-50.5M$-339.4M0.00x-100.0%
Bear Case11.0x10.0x$-61.7M$-221.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-61.7M$-263.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 42 hospitals with 106-426 beds
  • Same-state prioritization (n=43)
  • Comp margins: P25=-6.2% / P50=4.6% / P75=12.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.